5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] | 220100-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine]
• 英文别名: 5'-(3-Pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]；5'-pyridin-3-ylspiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
• CAS: 220100-25-4
• 化学式: C₁₈H₁₉N₃O
• 分子量: 293.368
• InChiKey: QKBVBFGEWWSUMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine] 、 、 三(邻甲基苯基)磷 、 氯化锂 、 3-(1,1,1-三丁基甲锡烷)嘧啶 以 乙二醇二甲醚 、 氯仿 、 甲醇 为溶剂， 反应 6.0h， 生成 5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine]
  参考文献：
  名称：

  Spiroazabicyclic Heterocyclic Compounds

  摘要：

  一种化合物的化学式为式中n，m，p，X，Y，W，A，G和D在规范中定义，其对映异构体，含有该化合物的制药组合物，其药学上可接受的盐，其在治疗中的用途，特别是用于治疗精神疾病和智力障碍。

  公开号：

  US20080153864A1

文献信息

• Spiroazabicyclic heterocyclic compounds
  申请人：——

  公开号：US20030166935A1

  公开（公告）日：2003-09-04

  A compound of formula 1 wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

  本发明涉及一种化合物，其化学式为1，其中n、m、p、X、Y、W、A、G和D如规范中所定义，其对映体，其药学上可接受的盐，制备它们的方法，含有它们的组合物，以及它们在治疗中的用途，特别是在治疗或预防精神障碍和智力障碍方面的用途。
• New compounds
  申请人：——

  公开号：US20020187994A1

  公开（公告）日：2002-12-12

  A compound of formula 1 wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H 2 or F 2 ; A is N or C(R 2 ); G is N or C(R 3 ); D is N or C(R 4 ); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R 1 is hydrogen or C 1 to C 4 alkyl; R 2 , R 3 , and R 4 are independently hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, aryl, heteroaryl, OH, OC 1 -C 4 alkyl, CO 2 R 1 , —CN, —NO 2 , —NR 5 R 6 , —CF 3 , —OSO 2 CF 3 or R 2 and R 3 , or R 3 and R 4 respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, aryl, heteroaryl, OH, OC 1 -C 4 alkyl, CO 2 R 1 , —CN, —NO 2 , —NR 5 R 6 , —CF 3 , —OSO 2 CF 3 ; R 5 and R 6 are independently hydrogen, C 1 -C 4 alkyl, C(O)R 7 , C(O)NHR 8 , C(O)OR 9 , SO 2 R 10 or may together be (CH 2 ) j Q(CH 2 ) k where Q is O, S, NR 11 , or a bond; j is 2 to 7, k is 0 to 2; R 7 , R 8 , R 9 , R 10 , and R 11 are independently C 1 -C 4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

  化合物的化学式为1，其中n为0或1；m为0或1；p为0或1；X为氧或硫；Y为CH、N或NO；W为氧、H2或F2；A为N或C（R2）；G为N或C（R3）；D为N或C（R4）；但是A、G和D中最多只有一个是氮，但Y、A、G和D中至少有一个是氮或NO；R1为氢或C1到C4烷基；R2、R3和R4独立地为氢、卤素、C1-C4烷基、C2-C4烯基、C2-C4炔基、芳基、杂环芳基、OH、OC1-C4烷基、CO2R1、-CN、-NO2、-NR5R6、-CF3、-OSO2CF3或R2和R3，或R3和R4可以分别形成另一个共用A和G或G和D的六元芳香或杂芳香环，其中包含零到两个氮原子，并且取代有以下一个或两个取代基：独立地为氢、卤素、C1-C4烷基、C2-C4烯基、C2-C4炔基、芳基、杂环芳基、OH、OC1-C4烷基、CO2R1、-CN、-NO2、-NR5R6、-CF3、-OSO2CF3；R5和R6独立地为氢、C1-C4烷基、C（O）R7、C（O）NHR8、C（O）OR9、SO2R10或可以共同为（CH2）jQ（CH2）k，其中Q为O、S、NR11或键；j为2到7，k为0到2；R7、R8、R9、R10和R11独立地为C1-C4烷基、芳基或杂环芳基，或其对映体，以及其药学上可接受的盐，制备它们的过程，包含它们的组合物以及它们在治疗中的应用，特别是在治疗或预防精神障碍和智力障碍方面。
• Spiroazabicyclic Heterocyclic Compounds
  申请人：Phillips Eifion

  公开号：US20080153864A1

  公开（公告）日：2008-06-26

  A compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, pharmaceutical compositions containing said compound, pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment of psychotic disorders and intellectual impairment disorders.

  一种化合物的化学式为式中n，m，p，X，Y，W，A，G和D在规范中定义，其对映异构体，含有该化合物的制药组合物，其药学上可接受的盐，其在治疗中的用途，特别是用于治疗精神疾病和智力障碍。
• Spiroazo bicyclic heterocyclic
  申请人：AstraZeneca AB

  公开号：US06703502B2

  公开（公告）日：2004-03-09

  A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C1 to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, C1, C4 alkyl, C2, C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1, C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3 or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3; R5 and R6 are independently hydrogen, C1-C4 alkyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CH2)jQ(CH2)k where Q is O, S, NR11, or a bond; j is 2 to 7, k is 0 to 2; R7, R8, R9, R10, and R11 are independently C1-C4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

  一种化合物的公式，其中n为0或1；m为0或1；p为0或1；X为氧或硫；Y为CH、N或NO；W为氧、H2或F2；A为N或C（R2）；G为N或C（R3）；D为N或C（R4）；但前提是A、G和D中最多只有一个是氮，但Y、A、G和D中至少有一个是氮或NO；R1为氢或C1至C4烷基；R2、R3和R4分别独立地为氢、卤素、C1、C4烷基、C2、C4烯基、C2-C4炔基、芳基、杂环芳基、OH、OC1、C4烷基、CO2R1、—CN、—NO2、—NR5R6、—CF3、—OSO2CF3或R2和R3或R3和R4可共同形成另一个六元芳香或杂芳环，共享A和G或G和D，其中含有零到两个氮原子，并置换有以下一到两个取代基：独立的氢、卤素、C1-C4烷基、C2-C4烯基、C2-C4炔基、芳基、杂环芳基、OH、OC1-C4烷基、CO2R1、—CN、—NO2、—NR5R6、—CF3、—OSO2CF3；R5和R6独立地为氢、C1-C4烷基、C（O）R7、C（O）NHR8、C（O）OR9、SO2R10或可共同为（CH2）jQ（CH2）k，其中Q为O、S、NR11或键；j为2至7，k为0至2；R7、R8、R9、R10和R11独立地为C1-C4烷基、芳基或杂环芳基或其对映异构体，以及其药学上可接受的盐，制备它们的过程，含有它们的组合物以及它们在治疗中的用途，特别是在治疗或预防精神障碍和智力障碍方面。
• Compounds
  申请人：Astra Zeneca AB

  公开号：US06369224B1

  公开（公告）日：2002-04-09

  A compound of formula wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H2 or F2; A is N or C(R2); G is N or C(R3); D is N or C(R4); with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R1 is hydrogen or C1 to C4 alkyl; R2, R3, and R4 are independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3 or R2 and R3, or R3 and R4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, OH, OC1-C4 alkyl, CO2R1, —CN, —NO2, —NR5R6, —CF3, —OSO2CF3; R5 and R6 are independently hydrogen, C1-C4 alkyl, C(O)R7, C(O)NHR8, C(O)OR9, SO2R10 or may together be (CH2)jQ(CH2)k where Q is O, S, NR11, or a bond; j is 2 to 7, k is 0 to 2; R7, R8, R9, R10, and R11 are independently C1-C4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

  该化合物的化学式为n为0或1；m为0或1；p为0或1；X为氧或硫；Y为CH，N或NO；W为氧，H2或F2；A为N或C（R2）；G为N或C（R3）；D为N或C（R4）；但是A，G和D中最多只有一个是氮，但Y，A，G和D中至少有一个是氮或NO；R1为氢或C1至C4烷基；R2，R3和R4分别独立地为氢，卤素，C1-C4烷基，C2-C4烯基，C2-C4炔基，芳基，杂环芳基，OH，OC1-C4烷基，CO2R1，-CN，-NO2，-NR5R6，-CF3，-OSO2CF3或R2和R3，或R3和R4共同形成另一个共用A和G或G和D的六元芳香或杂芳香环，其中含有零到两个氮原子，并用以下取代基之一或两个取代：独立的氢，卤素，C1-C4烷基，C2-C4烯基，C2-C4炔基，芳基，杂环芳基，OH，OC1-C4烷基，CO2R1，-CN，-NO2，-NR5R6，-CF3，-OSO2CF3；R5和R6独立地为氢，C1-C4烷基，C（O）R7，C（O）NHR8，C（O）OR9，SO2R10或共同为（CH2）jQ（CH2）k，其中Q为O，S，NR11或键；j为2到7，k为0到2；R7，R8，R9，R10和R11独立地为C1-C4烷基，芳基或杂环芳基，或其对映异构体，以及其药学上可接受的盐，制备它们的过程，包含它们的组合物，以及它们在治疗中的用途，特别是在治疗或预防精神障碍和智力障碍方面。